BRAF Mutations as Predictive Biomarker for Response to Anti‐EGFR Monoclonal Antibodies

Recently, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommended that patients with epidermal growth factor receptor (EGFR)‐expressing metastatic colorectal cancer could be treated with anti‐EGFR monoclonal antibodies (mAbs) cetuximab and pa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: van Brummelen, Emilie M. J., de Boer, Anthonius, Beijnen, Jos H., Schellens, Jan H. M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: AlphaMed Press 2017
Ämnen:
New Drug Development and Clinical Pharmacology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507642/
https://ncbi.nlm.nih.gov/pubmed/28576857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0031
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk